EC Approves Tepkinly as First Bispecific-Based Therapy for Follicular Lymphoma

  • Posted 2 hours ago by consumer451
  • 1 points
https://www.biopharminternational.com/view/european-commission-approves-tepkinly-plus-r2-as-first-bispecific-based-therapy-for-relapsed-or-refractory-follicular-lymphoma

1 comments

    Loading..